A Phase 1/2 interventional study of eFT226 and Sotorasib in Solid Tumor, Adult, sponsored by Effector Therapeutics. Recruiting at 14 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-21.
Sponsored by Effector Therapeutics · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This clinical trial is a Phase 1-2, open-label, sequential-group, dose-escalation and cohort-expansion study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of Zotatifin (eFT226) in subjects with selected advanced solid tumor malignancies.
Part 1 (Dose Escalation): Completed; Recommended Phase 2 Dose (RP2D) and Maximum Tolerated Dose (MTD) identified
Part 1a (Dose Escalation) This cohort will enroll patients with an advanced breast cancer that is refractory or intolerant to SOC therapy.
Part 1b (Dose Escalation) This cohort will enroll patients with an advanced breast cancer that is refractory or intolerant to SOC therapy.
Part 2 (Expansion Cohort) provides defined expansion cohorts to further explore the safety, pharmacology, and clinical activity of eFT226 monotherapy and in various combinations in subjects with previously treated advanced solid tumor malignancies.
Effector Therapeutics is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Criteria:
Parts 1a and 1b (Dose Escalation + Fulvestrant):
Patient has had prior chemotherapy, endocrine therapy, or other therapy as follows:
Cohort EMNK:
Cohort EMBF:
Patient has had prior chemotherapy, endocrine therapy, or other therapy as follows:
Cohort EMBH:
Patient has had prior chemotherapy, endocrine therapy, or other therapy as follows:
Cohort ECNS:
Cohort ECBF:
Patient has had prior chemotherapy, endocrine therapy, or other therapy as follows:
Cohort ECBF+A:
Patient has had prior chemotherapy, endocrine therapy, or other therapy as follows:
Cohort ECBT:
Cohort ECBF-D1:
Patient has had prior chemotherapy, endocrine therapy, or other therapy as follows:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
eFT226 administered IV weekly in 21-day cycles; dose escalated in sequential cohorts after subjects enrolled in a given cohort have completed DLT evaluation period.
Drug: eFT226
Cohort EMNK
Drug: eFT226
Cohort EMBF
Drug: eFT226
Cohort EMBH
Drug: eFT226
Cohort ECBF; Combination therapy partner administered per SOC at the approved dose.
Drug: Fulvestrant
Cohort ECNS; Combination therapy partner administered per SOC at the approved dose.
Drug: Sotorasib
Cohort ECBF+A; Combination therapy partner administered per SOC at the approved dose.
Drug: Fulvestrant · Drug: Abemaciclib
Cohort ECBT; Combination therapy partner administered per SOC at the approved dose.
Drug: Trastuzumab
eFT226 administered IV weekly in 21-day cycles. Fulvestrant will also be given. Dose escalations per protocol.
Drug: Fulvestrant
eFT226 administered IV every other week in 14-day cycles. Fulvestrant will also be given. Dose escalations per protocol.
Drug: Fulvestrant
ECBF-D1; Combination therapy partner administered per SOC at the approved dose.
Drug: Fulvestrant
eFT226 is a novel small-molecule, investigational drug being developed by eFFECTOR Therapeutics as an anticancer therapy. eFT226 is a potent and selective inhibitor of eIF4A1-mediated translation and selectively regulates the translation of a subset of mRNAs based on sequence specific recognition motifs in their 5'-UTR. eIF4A1 inhibition by eFT226 downregulates expression of receptor tyrosine kinases and KRAS, leading to decreased signaling through the PI3K/AKT and MAPK pathways. Preclinical efficacy testing of eFT226 demonstrates activity across models of solid tumor cancers with amplifications in HER2, FGFR1/2 and mutations in KRAS (including breast, NSCLC and CRC).
Also known as: Selective translation inhibitor
Recommended dosage: 960 mg orally once daily
Also known as: Lumarkus
500 mg administered intramuscularly on Days 1, 15, 29, and once monthly thereafter
Also known as: Faslodex
Dose in combination with fulvestrant: 150 mg twice daily
Also known as: Verzenia
600 mg every 3 weeks
Also known as: Herceptin
Parts 1a and 1b: MTD
determined by occurrence of first cycle DLTs within a 3+3 or 3+3+3 clinical trial design
Time frame: Through study completion, approximately 12 months
Parts 1a and 1b; incidence of AEs, serious adverse events (SAEs), and DLTs
according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)
Time frame: Through study completion, approximately 12 months
Parts 1a and 1b: RP2D
determined by Incidence and type of DLTs
Time frame: Through study completion, approximately 12 months
Parts 1a and 1b: RP2D
determine by Incidence, type, and severity of AEs and SAEs graded as per NCI CTCAE
Time frame: Through study completion, approximately 12 months
Part 2: Objective Response Rate- Efficacy
defined as confirmed Complete Response (CR) or Partial Response (PR)
Time frame: Through study completion, approximately 12 months
Part 2: (Combination Cohorts) Determine MTD
determined by occurrence of first cycle Dose Limiting Toxicities (DLTs) within the study design
Time frame: Through study completion, approximately 12 months
Part 2: (Combination Cohorts) Incidence, type, and severity of AEs and SAEs
via adverse event monitoring
Time frame: Through study completion, approximately 12 months
Part 2: (Combination Cohorts) Determine RP2D
determined by incidence and type of DLTs, and incidence, type, and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: Through study completion, approximately 12 months
Part 2: Percent change in tumor dimensions of target lesions- Efficacy
calculated by the percentage change from baseline in the sum of the LD of target lesions
Time frame: Through study completion, approximately 12 months
Part 2: Time to Response (TTR)- Efficacy
defined as the interval from the start of study therapy to the first documentation of an objective response
Time frame: Through study completion, approximately 12 months
Part 2: Duration of Response (DOR)- Efficacy
defined as the interval from the first documentation of objective response to the earlier of the first documentation of disease progression or death from any cause
Time frame: Through study completion, approximately 12 months
Parts 1a and 1b: Objective response
determined by confirmed CR or PR
Time frame: Through study completion, approximately 12 months
Parts 1a and 1b: Percent change in tumor dimensions of target lesions
calculated by the percentage change from baseline in the sum of the LD of target lesions
Time frame: Through study completion, approximately 12 months
Parts 1a and 1b: TTR
defined as the interval from the start of study therapy to the first documentation of an objective response
Time frame: Through study completion, approximately 12 months
Parts 1a and 1b: DOR
defined as the interval from the first documentation of objective response to the earlier of the first documentation of disease progression or death from any cause
Time frame: Through study completion, approximately 12 months
Parts 1a and 1b: PFS
defined as the interval from the start of study therapy to the earlier of the first documentation of disease progression or death from any cause
Time frame: Through study completion, approximately 12 months
Part 2: (Monotherapy and Combination Cohorts) Incidence and severity of AEs, SAEs, and additional safety parameters
via adverse event monitoring
Time frame: Through study completion, approximately 12 months
Part 2: Progression Free Survival
defined as the interval from the start of study therapy to the earlier of the first documentation of disease progression or death from any cause
Time frame: Through study completion, approximately 12 months
Evaluate plasma Pharmacokinetic (PK) parameters of eFT226
including area under the plasma concentration-time curve
Time frame: Through study completion, approximately 12 months
Evaluate plasma Pharmacokinetic (PK) parameters of eFT226
including maximum concentration
Time frame: Through study completion, approximately 12 months
Evaluate plasma Pharmacokinetic (PK) parameters of eFT226
including terminal phase rate constant
Time frame: Through study completion, approximately 12 months
Evaluate plasma Pharmacokinetic (PK) parameters of eFT226
including estimated steady-state volume of distribution \[Vss\]
Time frame: Through study completion, approximately 12 months
Evaluate plasma Pharmacokinetic (PK) parameters of eFT226
including half-life (t½)
Time frame: Through study completion, approximately 12 months
Evaluate plasma Pharmacokinetic (PK) parameters of eFT226
including total body clearance
Time frame: Through study completion, approximately 12 months
Evaluate plasma Pharmacokinetic (PK) parameters of eFT226including terminal state volume of distribution
including terminal state volume of distribution
Time frame: Through study completion, approximately 12 months
Evaluate plasma Pharmacokinetic (PK) parameters of eFT226 including terminal phase rate constant
including terminal phase rate constant
Time frame: Through study completion, approximately 12 months
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Plan to share: No — There is not a plan to make IPD available
No publications or documents are linked to this record.
Started Oct 2019 (actual). Primary completion is estimated for Dec 2024, 62 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Zotatifin · Sotorasib
Effector Therapeutics